PSCK9 Battle: Sanofi Not Negotiating Praluent Fate With Amgen; Ruling Possible By June
Executive Summary
Sanofi attorneys describe three possible outcomes of fight over injunction and validity of Repatha patents, and contrast litigation to other patent disputes where innovators did not seek removal of innovator product from market.
You may also be interested in...
Amgen Hit By Enbrel 'Peculiarities' And Repatha Resistance
Amgen reported a surprising double-digit decline for Enbrel during the first quarter and sales for the cholesterol-lowering biologic Repatha showed that the PCSK9 inhibitor is not going to make up for the company's declining revenue any time soon – at least not while payers continue to block its use.
What To Look Out For At ACC
Amgen has already reported the positive topline result of its FOURIER cardiovascular outcomes trial for its PCSK9 inhibitor Repatha, but analysts from Datamonitor Healthcare and Biomedtracker lay out the reasons to check out the full results and other highlights at the upcoming American College of Cardiology meeting.
Biosimilars Could Face 'Litigation Backlog' Without Patent Reforms, AAM Fears
Category is still in its infancy, but the newly renamed generic association worries that products might never reach their full potential if launches are substantially delayed by IP disputes.